BioSourcing SA announces the appointment of Maxime Wallerand as Chief Financial Officer

Bio-Sourcing SA, a Belgium-based biotherapeutics company, is pleased to announce that Maxime Wallerand has been appointed CFO as of January 2, 2025, taking over from Mathieu Delveaux. Maxime brings over two decades of extensive finance experience across the biotechnology, consumer and audit sectors.

Maxime’s previous roles include  CFO of The Akkermansia Company, a microbiome health scale up, where he was instrumental in raising over €30 million in financing and supporting the company’s transition to a commercial-stage organization. He also held multiple finance roles at GSK Vaccines, including Chief of Staff to the Global CFO, where he supported both the R&D, manufacturing and commercial organizations as well as helped on the post-acquisition integration of Novartis Vaccines. He also served as CFO at Chocolaterie Galler, and worked as auditor at PricewaterhouseCoopers Belgium and Canada.

The Company is also very pleased to announce that Mathieu Delveaux will stay on board with a function of Corporate Development Director effective January 2, 2025, where he will bring his experience of CFO the company since 2015 into future corporate and business development opportunities.

Bio-Sourcing SA has developed a proprietary technological platform, BioMilk, to express biotherapeutics, e.g., monoclonal antibodies, in the milk of specialized goats, using genome editing and nuclear transfer technologies. This enables to produce biotherapeutics in a much more competitive way, both in terms of cost and environmental footprint, than the traditional production approaches.

At Bio-Sourcing’s, we make biotherapeutics more available, affordable and sustainable  for everyone.